XR 9051

Drug Profile

XR 9051

Alternative Names: XR-9051

Latest Information Update: 29 Jul 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Xenova Group
  • Class Antineoplastics; Benzylidene compounds; Isoquinolines
  • Mechanism of Action P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 29 Jul 2004 Discontinued - Phase-I for Cancer in United Kingdom (unspecified route)
  • 18 Jan 2001 Profile reviewed but no significant changes made
  • 12 Mar 1998 Suspended-I for Cancer in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top